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Abstract
Background: Folic acid taken in early pregnancy reduces risks for delivering offspring with several congenital anomalies. The
mechanism by which folic acid reduces risk is unknown. Investigations into genetic variation that influences transport and
metabolism of folate will help fill this data gap. We focused on 118 SNPs involved in folate transport and metabolism.
Methods: Using data from a California population-based registry, we investigated whether risks of spina bifida or conotruncal
heart defects were influenced by 118 single nucleotide polymorphisms (SNPs) associated with the complex folate pathway. This
case-control study included 259 infants with spina bifida and a random sample of 359 nonmalformed control infants born during
1983–86 or 1994–95. It also included 214 infants with conotruncal heart defects born during 1983–86. Infant genotyping was
performed blinded to case or control status using a designed SNPlex assay. We examined single SNP effects for each of the 118
SNPs, as well as haplotypes, for each of the two outcomes.
Results: Few odds ratios (ORs) revealed sizable departures from 1.0. With respect to spina bifida, we observed ORs with 95%
confidence intervals that did not include 1.0 for the following SNPs (heterozygous or homozygous) relative to the reference
genotype: BHMT (rs3733890) OR = 1.8 (1.1–3.1), CBS (rs2851391) OR = 2.0 (1.2–3.1); CBS (rs234713) OR = 2.9 (1.3–6.7);
MTHFD1 (rs2236224) OR = 1.7 (1.1–2.7); MTHFD1 (hcv11462908) OR = 0.2 (0–0.9); MTHFD2 (rs702465) OR = 0.6 (0.4–0.9);
MTHFD2 (rs7571842) OR = 0.6 (0.4–0.9); MTHFR (rs1801133) OR = 2.0 (1.2–3.1); MTRR (rs162036) OR = 3.0 (1.5–5.9); MTRR
(rs10380) OR = 3.4 (1.6–7.1); MTRR (rs1801394) OR = 0.7 (0.5–0.9); MTRR (rs9332) OR = 2.7 (1.3–5.3); TYMS (rs2847149) OR
= 2.2 (1.4–3.5); TYMS (rs1001761) OR = 2.4 (1.5–3.8); and TYMS (rs502396) OR = 2.1 (1.3–3.3). However, multiple SNPs
observed for a given gene showed evidence of linkage disequilibrium indicating that the observed SNPs were not individually
contributing to risk. We did not observe any ORs with confidence intervals that did not include 1.0 for any of the studied SNPs
with conotruncal heart defects. Haplotype reconstruction showed statistical evidence of nonrandom associations with TYMS,
MTHFR, BHMT and MTR for spina bifida.
Conclusion: Our observations do not implicate a particular folate transport or metabolism gene to be strongly associated with
risks for spina bifida or conotruncal defects.
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Periconceptional vitamin supplementation with folic acid
substantially reduces risks of women having neural tube
defect-affected pregnancies [1,2] and has been implicated
in reducing risks of several other congenital anomalies,
including orofacial clefts and selected heart defects [3-11].
Mechanisms underlying these reduced risks have not been
elucidated, although it has been speculated that supple-
mentation with vitamins containing folic acid restores
some normal developmental function that is genetically
compromised in selected infants.
Investigating genetic variation that influences cellular
absorption, transport, and metabolism of folate may offer
insight into this unknown developmentally protective
mechanism. Indeed, numerous investigations of genes
that are specifically involved with folate metabolism have
yielded at least one gene, 5, 10-methylenetetrahydrofolate
reductase (MTHFR), that has been associated with a mod-
est increased risk of neural tube defects (e.g., [12-17]), and
possibly heart defects [18,19]. Observed risks with the two
principal MTHFR variants, however, do not appear to
account for a large proportion of the etiologic fraction of
any of these defects, under the assumption that MTHFR
variants have a causal role [17]. Thus, further investigation
of other folate-related genes is necessary to reveal clues
about mechanisms underlying the potential embryonic
protective effects of folic acid supplementation.
We hypothesized that genetic susceptibility of fetal metab-
olism or transport of folate puts fetuses at risk for selected
congenital anomalies. Using population-based data, we
investigated 118 single nucleotide polymorphisms
(SNPs) in 14 genes in the complex folate pathway as risk
factors for spina bifida and conotruncal heart defects.
Methods
This population-based case-control study included infants
with spina bifida or conotruncal heart defects diagnosed
within 1 year after birth among infants and fetal deaths
delivered to women residing in most California counties.
Data were derived from the California Birth Defects Mon-
itoring Program [20], a population-based active surveil-
lance system for collecting information on infants and
fetuses with congenital malformations. Diagnostic and
demographic information was collected by program staff
from multiple sources of medical records for all liveborn
and stillborn fetuses (defined as >20 weeks gestation).
Overall ascertainment for major malformations has been
estimated as 97% complete [21]. Eligible were live born
infants only because the source of DNA was from new-
born screening cards.
Included were 259 infants with spina bifida and a random
sample of 359 nonmalformed control infants born during
1983–86 and 1994–95 in selected counties in California.
Also included for study were 214 infants with conotruncal
heart defects, specifically d-transposition of the great
arteries and tetralogy of Fallot. The random sample of
1983–86 controls for conotruncal heart defects included
220 of the overall 359. Newborn bloodspots were
obtained from the State of California and their use in this
study was consistent with the consent procedures at the
time of sample collection. The protocol for this study was
reviewed and approved by the State of California Health
and Welfare Agency Committee for the Protection of
Human Subjects.
Genomic DNA was extracted from dried blood spots on
filter paper using the Puregene DNA Extraction Kit (Gen-
tra, Minneapolis, MN). Prior to genotyping, genomic
DNA was amplified using a commercial multiple dis-
placement amplification (MDA) kit, GenomePhi (GE
Healthcare, Piscataway, NJ). The MDA method relies on
isothermal amplification using the DNA polymerase of
the bacteriophage phi29 and is a recently developed tech-
nique for high performance WGA. MDA has been demon-
strated to be reliable for genotyping, with the most
favorable call rates, best genomic coverage, and lowest
amplification bias [22]. Studies indicate no discernable
difference between WGA samples with GenomiPhi kit
and the original DNA templates [23,24]. The whole
genome amplification (WGA) product was then quanti-
fied using RNase P method (AppliedBiosystems, Foster
City, CA). 150 ng WGA product was then used for each
SNPlex assay pool which contained about 48 SNPs.
Genotype analyses were performed using SNPlex assays
(AppliedBiosystems, Foster City, CA). SNP markers were
selected using the SNPBrowser™ program (version 3.0)
provided by AppliedBiosystems Inc. This program
allowed selection of SNP markers from the HapMap data-
base. For each target gene, tagging SNPs were selected
based on the pairwise r2 > = 0.8. SNPs with minor allele
frequencies lower than 10% in Caucasians were excluded.
All validated non-synonymous SNPs were included. Suc-
cessful rates for SNPlex assays were >96% for 75 SNPs,
from 90% to 96% for 32 SNPs, from 70% to 90% for 7
SNPs. 15 SNPs suffered from more than 30% failure rates.
In a subsequent effort to fill in the missing genotyping
data and obtain higher call rate, we performed TaqMan
SNP assays (Appliedbiosystems, Foster City, CA) for 22 of
these SNPs on an ABI 7900 Genetic Analyzer.
All genotyping was performed blinded to subject's case or
control status. Case and control infants were genotyped
for 129 SNPs. Failure to obtain unambiguous genotype
data on >50% of the samples for 11 SNPs (CBS rs1801181
and rs12329790; MTHFR rs1537514 and rs7533315;
MTR rs10925257, NOS3 rs1800780 and hcv11631000;Page 2 of 11
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rs7278825) resulted in their elimination from further
analyses. The remaining 118 SNPs are shown in Table 1.
The percentage of control study subjects (percentages were
similar for cases) for whom genotype could be assigned is
also shown in Table 1.
Genotypes among controls were analyzed to verify that
their distributions fit Hardy-Weinberg expectations. Gen-
otypes for each SNP were statistically consistent with
Hardy-Weinberg expectations. Odds ratios and 95% con-
fidence intervals (CI) were used to estimate risks. These
measures were calculated using SAS software (version
9.1). Information on maternal race/ethnicity was
obtained for case and control infants from California
birth certificates. Logistic regression was used to compute
risk estimates adjusted for maternal race/ethnicity (white
Hispanic; white nonHispanic, and other). Analyses esti-
mated defect risks (spina bifida or conotruncal heart
defects) for each SNP assuming a recessive model, i.e.,
homozygous variant genotype compared to homozygous
reference genotype and heterozygous variant genotype
compared to homozygous reference genotype. In addition
to single SNP-at-a-time analyses, we explored haplotype
block analyses. Haplotype analyses were performed using
Haploview version 3.32. Identified blocks were assessed
with odds ratios.
Results
Numbers of case and control infants stratified by race/eth-
nicity are shown in Table 2. These data show the expected
greater frequency of Hispanics in the spina bifida case
group.
We examined risks for each of the 118 SNPs and for each
of the two birth defect outcome (Additional file 1). Few
odds ratios (ORs) revealed sizable departures from 1.0.
Given the large number of comparisons (n = 472) we
expected more ORs to be substantially different from 1.0
by chance. With respect to spina bifida, we observed ORs
with confidence intervals that did not include 1.0 for the
following SNPs (heterozygous or homozygous) relative to
the reference genotype: BHMT (rs3733890) OR = 1.8
(1.1–3.1), CBS (rs2851391) OR = 2.0 (1.2–3.1); CBS
(rs234713) OR = 2.9 (1.3–6.7); MTHFD1 (rs2236224)
OR = 1.7 (1.1–2.7); MTHFD1 (hcv11462908) OR = 0.2
(0–0.9); MTHFD2 (rs702465) OR = 0.6 (0.4–0.9);
MTHFD2 (rs7571842) OR = 0.6 (0.4–0.9); MTHFR
(rs1801133) OR = 2.0 (1.2–3.1); MTRR (rs162036) OR =
3.0 (1.5–5.9); MTRR (rs10380) OR = 3.4 (1.6–7.1); MTRR
(rs1801394) OR = 0.7 (0.5–0.9); MTRR (rs9332) OR = 2.7
(1.3–5.3); TYMS (rs2847149) OR = 2.2 (1.4–3.5); TYMS
(rs1001761) OR = 2.4 (1.5–3.8); and TYMS (rs502396)
OR = 2.1 (1.3–3.3). Each gene involving multiple SNP
associations was investigated for linkage disequilibrium.
Modest to strong evidence for linkage disequilibrium was
observed for SNPs in each gene, i.e., D' ranged from 0.44
to 1.0 with all p values < 10-4. With respect to conotruncal
heart defects, we did not observe any OR with a confi-
dence interval that did not include 1.0.
We did not observe evidence to indicate that risk patterns
were confounded by race/ethnicity groupings, i.e.,
observed ORs were not substantially altered after adjust-
ing for maternal race/ethnicity (not shown, available from
authors upon request).
Haplotypes, reconstructed for each gene based on studied
SNPs, were explored to assess risks for each case group. A
total of 77 of the 118 studied SNPs formed 17 haplotype
blocks. As shown in Table 3, blocks for TYMS, MTHFR,
BHMT, and MTR showed some evidence of nonrandom
effects for spina bifida. For each of these haplotypes we
observed decreased risk associated with the lower fre-
quency haplotype relative to the most frequent haplotype.
Similar to SNP analyses, haplotype analyses for conotrun-
cal heart defects did not reveal evidence of nonrandom
effects, with the exception of one haplotype block for MTR
(Table 4).
Haplotype analyses were stratified by race/ethnic back-
ground (Hispanic white and nonHispanic white). We
observed evidence of a nonrandom haplotype association
with TYMS for spina bifida and conotruncal heart defects
among nonHispanic whites. Lack of evidence for other
haplotypes that were observed overall was likely the result
of smaller sample sizes from stratification.
Discussion
In this California population we found only modest evi-
dence that polymorphisms in 14 folate-related genes con-
tributed to risk of spina bifida. SNPs contributing risks
were in BHMT, CBS, MTHFD1, MTHFD2, MTHFR, MTRR,
and TYMS. Haplotype association analyses further identi-
fied TYMS and MTHFR as potential contributors to spina
bifida risk. In general, however, most of these folate-
related genes showed little evidence for a gene-only effect
on risk of spina bifida, and even less, on risks of conotrun-
cal heart defects.
The 14 genes studied here have been implicated in the
complex metabolic cycle involving folate (e.g., [25-27]).
To our knowledge, this study contained the largest
number of SNPs in folate-related genes interrogated as
risk factors for human spina bifida or conotruncal heart
defects. Previous studies have included some of the SNPs
examined here. For example, Boyles and colleagues [28]
studied 28 SNPs in 11 folate-related genes and found that
only BHMT (rs3733890) was associated with increasedPage 3 of 11
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Gene Change Chromosome Base Position SNP_ID Type/Comment Percent Genotyped1
BHMT R (A/G) 5 78457715 rs3733890 exon, nonsynonymous R239Q 100
BHMT Y (C/T) 5 78471967 rs1915706 Intergenic/Unknown 96.4
BHMT (G/C) 5 78567093 rs1316753 Tag, BHMT 100
BHMT M (C/A) 5 78465350 rs617219 intergenic 96.4
BHMT M (A/C) 5 78438303 rs645112 Intergenic/Unknown 96.9
BHMT W (A/T) 5 78462964 rs585800 untranslated region 94.2
BHMT S (C/G) 5 78559288 rs3829809 Tag, BHMT 100
BHMT Y (C/T) 5 78452172 rs567754 intron 95.8
BHMT2 M (A/C) 5 78400443 rs642431 intergenic-BHMT2;intron-DMGDH 91.1
BHMT2 R (A/G) 5 78405657 rs626105 intron 96.1
BHMT2 Y (C/T) 5 78409187 rs682985 exon, synonymous 95.5
BHMT2 M (A/C) 5 78387392 rs2253262 exon, synonymous 96.4
BHMT2 K(G/T) 5 78402082 rs670220 Validated 96.7
BHMT2 R (A/G) 5 78404048 rs592052 intron 99.2
BHMT2 R (A/G) 5 78419219 rs597560 intron 98.3
CBS Y (T/C) 21 43360473 rs2851391 intron 92.5
CBS R (A/G) 21 43359173 rs2298759 intron 72.4
CBS Y (T/C) 21 43361102 rs234714 intron 90
CBS S (C/G) 21 43346936 rs1051319 untranslated region 91.9
CBS Y (T/C) 21 43376503 rs234784 Tag, CBS 99.7
CBS N (A/C/G/T) 21 43346760 rs12613 untranslated region 92.5
CBS S (C/G) 21 43377074 rs234785 Tag, CBS 100
CBS R (A/G) 21 43360960 rs234713 intron 91.1
CBS Y (C/T) 21 43376312 rs234783 Tag, CBS 100
DHFR Y(C/T) 5 79986537 rs1650697 Validated nsSNP 92.2
DHFR W(A/T) 5 79957572 rs12109877 Validated 94.2
DHFR Y(C/T) 5 79987790 rs380691 Validated 95.5
DHFR M(A/C) 5 79985331 rs1478834 Validated 96.4
DHFR Y(C/T) 5 79966012 rs1643638 Validated 92.8
DHFR M(A/C) 5 79961366 rs2618372 Validated 96.9
DHFR R (A/G) 5 79980489 rs13161245 Validated 96.1
DHFR Y(C/T) 5 79975899 rs1643650 Validated 94.7
DHFR K(G/T) 5 79981467 rs836821 Validated 97.5
FOLR1 Y (C/T) 11 73373406 rs1540087 untranslated region 95.8
FOLR1 W (T/A) 11 73380857 rs11235462 Tag, FOLR1 100
FOLR1 R (A/G) 11 73372879 rs2071010 untranslated region 91.9
FOLR2 R (A/G) 11 73404256 rs2298444 intron 92.2
FOLR2 R (A/G) 11 73402049 rs514933 intron 100
FOLR2 W (A/T) 11 73401368 rs651646 untranslated region 100
MTHFD1 Y (C/T) 14 63984935 rs2236222 intron 95.5
MTHFD1 Y (C/T) 14 63978904 rs2236224 intron 97.8
MTHFD1 Y (C/T) 14 63952133 rs1950902 exon, nonsynonymous 90.5
MTHFD1 Y (C/T) 14 63978598 rs2236225 exon, nonsynonymous G1958A (R653Q) 100
MTHFD1 (T/A) 14 63999040 hCV11462908 Tag, MTHFD1 100
MTHFD1 R (A/G) 14 63957808 hCV11660794 intron 95.3
MTHFD1 R (A/G) 14 63988165 rs11849530 intron 95.8
MTHFD1 R (A/G) 14 63990418 rs1256146 intron 95
MTHFD1 Y (C/T) 14 63985918 rs10137921 exon, nonsynonymous 96.4
MTHFD1 Y (C/T) 14 63980547 rs1256142 intron 97.8
MTHFD2 Y (T/C) 2 74304595 rs11126426 Intergenic, Tag 100
MTHFD2 (T/A) 2 74280806 rs702465 Intergenic, Tag 96.7
MTHFD2 R (A/G) 2 74313429 rs1667599 Intergenic, Tag 100
MTHFD2 R (A/G) 2 74340847 rs1667627 Validated 96.1
MTHFD2 W (A/T) 2 74333849 rs828858 Intergenic, Tag 100
MTHFD2 (C/G) 2 74281605 rs702466 Intergenic, Tag 99.7
MTHFD2 R (A/G) 2 74372559 rs7571842 Intergenic, Tag 100
MTHFD2 R (A/G) 2 74348376 rs828903 Validated 94.4
MTHFR R (A/G) 1 11801310 rs3737964 Validated 95.8
MTHFR R (A/G) 1 11823734 rs535107 Intergenic, Tag 93.3
MTHFR K(G/T) 1 11798240 rs1931226 Validated 96.9Page 4 of 11
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MTHFR Y (C/T) 1 11796598 rs7525338 Validated 97.5
MTHFR R (A/G) 1 11785193 rs2274976 exon, nonsynonymous 93
MTHFR Y (C/T) 1 11792217 rs4846052 intron 96.9
MTHFR Y (C/T) 1 11790644 rs1801133 exon, nonsynonymous C677T 99.4
MTHFR R (A/G) 1 11775209 rs1889292 Intergenic, Tag 100
MTHFR Y (C/T) 1 11797323 rs2066470 exon, synonymous 95.3
MTHFR R (A/G) 1 11788723 rs4846051 exon, synonymous 93
MTHFR R (A/G) 1 11786566 rs1476413 intron 93.9
MTHFR M (A/C) 1 11788742 rs1801131 exon, nonsynonymous A1298C 99.7
MTR M (A/C) 1 233374717 rs2275565 Validated 96.1
MTR Y (C/T) 1 233322616 rs1806505 intron 97.5
MTR K(G/T) 1 233386474 rs3820571 Validated 96.1
MTR Y (C/T) 1 233335898 rs3754255 Validated 94.7
MTR S(C/G) 1 233381346 rs10802569 Validated 96.1
MTR R (A/G) 1 233376992 rs1266164 intron 96.1
MTR R (A/G) 1 233374541 rs1805087 exon, nonsynonymous A2756G 96.4
MTR W(A/T) 1 233385428 rs4659743 Validated 98.3
MTR K(G/T) 1 233390667 rs6676866 Validated 98.3
MTR S(C/G) 1 233315110 rs12060570 Validated 98.6
MTR W(A/T) 1 233306545 rs955516 Validated 99.2
MTR K (G/T) 1 233313831 rs4077829 intron 96.7
MTR R (A/G) 1 233364202 rs1770449 intron 94.4
MTR S (C/G) 1 233353709 rs3768139 intron 95.5
MTR R (A/G) 1 233300165 rs4659724 intron 97.2
MTR Y (C/T) 1 233327367 rs6668344 intron 96.4
MTR R (A/G) 1 233367345 rs7367859 Validated 93.9
MTR K (G/T) 1 233354605 rs3768142 Validated 96.1
MTR Y (C/T) 1 233348403 rs10925252 Validated 96.9
MTR R (A/G) 1 233380610 rs2229276 exon, synonymous 95
MTR R (A/G) 1 233388346 rs1050993 untranslated region 97.2
MTRR R (A/G) 5 7938959 rs162036 Validated nsSNP Lys/Arg 95.5
MTRR S (C/G) 5 7944506 rs16879334 exon, nonsynonymous Pro/Arg 90
MTRR R (G/A) 5 7950319 rs1802059 exon, synonymous 94.7
MTRR R (G/A) 5 7942216 rs2287779 exon, synonymous 97.2
MTRR R (A/G) 5 7927847 rs326120 intron 87.7
MTRR Y (C/T) 5 7950191 rs10380 exon, nonsynonymous, His/Tyr 96.4
MTRR R (A/G) 5 7923973 rs1801394 exon, nonsynonymous 96.7
MTRR Y (C/T) 5 7953712 rs9332 UTR 92.2
MTRR S (C/G) 5 7938907 rs10064631 exon, nonsynonymous 95
MTRR W (A/T) 5 7931424 rs2303080 exon, nonsynonymous 96.1
MTRR R (A/G) 5 7949511 rs3776455 intron 95
MTRR R (A/G) 5 7931179 rs1532268 exon, nonsynonymous 95
MTRR R (A/G) 5 7945310 rs162048 intron 98.6
NOS3 R (A/G) 7 150145737 rs891512 intron 86.6
NOS3 R (A/G) 7 150127591 rs1800779 untranslated region 87.5
NOS3 Y (C/T) 7 150148555 rs3918211 exon, synonymous 96.9
RFC1 K (G/T) 21 45761011 rs3788189 intron 81.1
RFC1 R (A/G) 21 45755537 rs12483377 Tag, RFC 100
RFC1 R (A/G) 21 45756112 rs2236484 Intron, Tag 98.6
RFC1 R (A/G) 21 45761386 rs3788190 Intron, Tag 91.1
RFC1 S (C/G) 21 45750430 rs10483080 intron 99.7
RFC1 Y (C/T) 21 45777720 rs2330183 intron 91.4
TYMS Y (C/T) 18 652215 rs11540152 exon, nonsynonymous 95.8
TYMS Y (C/T) 18 660414 rs2853532 intron 96.4
TYMS R (A/G) 18 656371 rs2847149 intron 97.2
TYMS Y (C/T) 18 652103 rs1001761 intron 98.9
TYMS Y (C/T) 18 649236 rs502396 intron 97.8
1Percent of 359 controls genotyped for each SNP.
Abbreviations: BHMT = betaine homocysteine methyltransferase; BHMT2 betaine homocysteine methyltransferase-2; CBS = cystathione beta 
synthase; DHFR = dihydrofolate reductase; FOLR1 folate receptor 1; FOLR2 folate receptor 2; MTHFD1 = methylenetetrahydrofolate dehydrogenase 
1; MTHFD2 = methylenetetrahydrofolate dehydrogenase 2; MTHFR = methylenetetrahydrofolate reductase; MTR = methionine synthase; MTRR = 
methionine synthase reductase; NOS3 = nitric oxide synthase; RFC1 = reduced folate carrier 1; TYMS = thymidylate synthase.
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our findings that showed an odds ratio of 1.8 (1.1–3.1).
Many studies have explored MTHFR 677 (rs1801133)
polymorphism. A range of risks, including no-effect, has
been reported for this SNP relative to spina bifida. Botto
and Yang [15] in a meta-analysis demonstrated a pooled
odds ratio of 1.8 for spina bifida among infants
homozygous for 677T. A few studies have also explored
this 677 SNP in MTHFR as a risk factor for selected con-
genital heart defects, with most investigations finding no
or little association [18,19,29-31]. We did observe a 2-
fold increased risk of spina bifida associated with this SNP
for homozygous infants. Further, haplotype analyses
showed some association for the MTHFR gene as well.
Methionine synthase (MTR) is a vitamin B12 dependent
enzyme that is essential for the remethylation of homo-
cysteine to methionine. The enzyme is required by cells
for the essential accumulation of folate [32]. One particu-
lar SNP (A2756G; rs1805087) has been considerably
investigated, with increased risks of NTDs reported in
some studies [33-35], but not in others [36,37]. We did
not find an increased risk for spina bifida or conotruncal
heart defects associated with this SNP or any other SNP of
MTR.
Cystathione beta synthase (CBS) is critical to the degrada-
tion of homocysteine to cysteine. Regulation of this pyri-
doxal phosphate-dependent enzyme catalyzes the
hydroxyl group of serine with the thiolate of homo-
cysteine [38]. The polymorphism in the CBS gene that has
received the most study is a 68 bp insertion (844ins68),
with predominantly no associations observed for NTDs
[27]. This polymorphism was not investigated in the cur-
rent study. We did observe, however, two CBS SNPs
(rs2851391 and rs234713) that showed increased risks
for spina bifida. Boyles et al [28], albeit using a different
study design than ours, observed that these two SNPs were
not differentially transmitted from parents of infants with
spina bifida.
MTRR gene polymorphisms (particularly rs1801394)
have been investigated as a risk factor for both spina bifida
and congenital heart defects. Polymorphisms in MTRR
could alter homocysteine levels because methionine syn-
thase reductase participates in maintaining the vitamin
B12-dependent conversion of homocysteine to methio-
nine [32]. The most frequently studied MTRR polymor-
phism has been the 66A>G (rs1801394). This
polymorphism in infants was associated with a 2.6-fold
increased risk of spina bifida in an earlier study by us [33],
it was associated with increased risk for spina bifida in
another study only when vitamin B12 levels were low [39],
or in combination with MTHFR CC genotype [35]. The
polymorphism in mothers of infants with neural tube
defects has been associated with increased risk in one
study [40], but not in another study [41]. Recent work
from the Netherlands has shown a lack of association
between this polymorphism and risk for conotruncal
heart defects [42] as well as no increased risks for a
broader phenotypic group of heart defects [43]. In this
study, the 66A>G polymorphism was not associated with
increased risks for either spina bifida or conotruncal heart
defects. We did observe, however, approximately 3-fold
elevated risks for spina bifida associated with three other
MTRR SNPs (rs162036, rs10380, and rs9332). The signif-
icance of these observations will have to be explored in
future studies.
With respect to MTHFD1 and MTHFD2, two studies have
demonstrated an association with one polymorphism (rs
2236225) in MTHFD1 and NTD risk. One study showed
a 1.5-fold increase in risk of an NTD-affected pregnancy in
Irish women who were homozygous AA [44], a finding
that confirmed an earlier increased risk that was identified
in Irish women. Another study showed a similar risk for
Italian women as well as a 1.9-fold risk for infants with the
AA genotype to have spina bifida [45]. For this particular
SNP, we observed a similar magnitude of risk (OR = 1.6)
for infants with the homozygous genotype, but the esti-
mate was relatively imprecise. We did observe a modestly
elevated spina bifida risk for individuals who were
homozygous for another MTHFD1 SNP (rs2236224) and
modestly lowered risks for three others (hcv11462908,
rs702465, and rs7571842). These observations will need
to be replicated in future studies.
Polymorphisms in the DHFR gene have not been well-
studied for their role in risks of birth defects. Three studies
have investigated a 19-bp deletion with mixed results [46-
48]. That particular polymorphism was not interrogated
in the current study.
Table 2: Racial/ethnic percentages of malformed cases and non-
malformed controls, California 1983–86 and 1994–95.
Spina Bifida Conotruncal Heart
Cases
n = 259
%2
Controls
n = 359
%2
Cases
n = 214
%2
Controls
n = 2201
%2
Race/Ethnicity
White, Hispanic 50.6 31.5 17.8 18.6
White, nonHispanic 35.9 47.4 53.3 61.8
Other 12.0 20.6 26.2 18.6
1The number of controls born in the period 1983–86 among the 359 
selected for the overall study period 1983–86 and 1994–95. The 220 
represent the birth years of cases with conotruncal heart defects.
2Percentages may not equal 100 owing to missing data or rounding.Page 6 of 11
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Haplotype Block Frequency Odds Ratio (95% CI)
TYMS
CGC 0.500 REF
TAT 0.373 0.7 (0.6–0.9)
TAC 0.115 0.5 (0.3–0.7)
MTRR
ATTAGCAACAC 0.264 REF
ACTGGCAGTGT 0.213 1.4 (1.0–1.9)
ACTAGCAACGC 0.201 0.8 (0.6–1.1)
GCTAGCGGCGC 0.162 1.1 (0.7–1.5)
ACAAAGAGCGC 0.055 1.1 (0.7–1.9)
ACTAGCAGCGC 0.034 0.6 (0.3–1.3)
ACTAAGAGCGC 0.027 1.2 (0.6–2.6)
ACTGGCAGCGT 0.011 1.4 (0.5–4.1)
MTHFR*
GGG 0.656 REF
AGA 0.163 0.9 (0.6–1.2)
AGG 0.121 0.9 (0.6–1.2)
AAA 0.057 0.6 (0.3–1.0)
MTHFR**
TCCCA 0.368 REF
CCCCA 0.231 0.7 (0.5–0.9)
CTCTG 0.180 0.8 (0.6–1.1)
CTTCG 0.099 0.6 (0.4–0.9)
CTCCG 0.063 0.7 (0.5–1.2)
CTCCA 0.037 1.0 (0.5–1.8)
CBS
CG 0.889 REF
TC 0.055 1.2 (0.7–1.9)
CC 0.053 0.6 (0.3–1.0)
RFC1*
CG 0.856 REF
GG 0.079 1.1 (0.7–1.7)
GA 0.063 1.0 (0.6–1.6)
RFC1**
TG 0.486 REF
GA 0.463 0.9 (0.7–1.2)
GG 0.046 0.6 (0.3–1.0)
MTHFD1*
CT 0.486 REF
TC 0.429 1.3 (1.0–1.6)
CC 0.080 0.9 (0.6–1.4)
MTHFD1**
GT 0.825 REF
AA 0.167 0.9 (0.6–1.2)
FOLR2
TA 0.549 REF
AG 0.356 1.0 (0.8–1.3)
AA 0.093 1.0 (0.7–1.6)
MTHFD2*
TA 0.589 REF
CA 0.321 1.1 (0.9–1.4)
CG 0.089 1.1 (0.7–1.6)
MTHFD2**
TC 0.388 REF
TT 0.332 1.2 (0.9–1.5)
AT 0.276 1.0 (0.8–1.4)
BHMT2
GGGTCA 0.466 REF
TAACTC 0.219 1.0 (0.7–1.3)Page 7 of 11
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RFC1. Previous investigations of this gene have focused
on a particular SNP, rs1051266, and have found mixed
results [37,41,49-53]. This particular SNP was not ana-
lyzed here as a result of too many samples failing to be
genotyped for this SNP using the SNPlex platform.
Recent studies have focused on the importance of TYMS
in the folate metabolic pathway, including associations
between TYMS polymorphisms and folate levels [54-56].
This folate-dependent enzyme catalyzes the reductive
methylation of deoxyuridylate (dUMP) to thymidylate
(dTMP), thereby playing a central role in DNA synthesis
and repair by serving as the primary intracellular source of
dTMP [54,57-59]. We previously [56] observed a 4-fold
increased risk of spina bifida in nonHispanic white
infants who had a polymorphism for a 28 bp insertion in
the promoter region. This observation, however, was not
replicated in a population from the northern UK [55].
This particular polymorphism was not interrogated in the
GAGCTC 0.171 1.1 (0.8–1.6)
GAGTCA 0.091 1.0 (0.6–1.5)
GGGTCC 0.022 0.7 (0.3–1.7)
BHMT*
CAA 0.339 REF
TGA 0.326 0.7 (0.5–0.9)
CGT 0.172 0.7 (0.5–1.0)
CGA 0.158 0.9 (0.6–1.2)
BHMT**
AC 0.501 REF
CT 0.373 0.8 (0.7–1.1)
AT 0.120 0.9 (0.6–1.3)
DHFR
CTTACCA 0.402 REF
CTTACCG 0.390 0.9 (0.7–1.2)
ACCGAAA 0.201 0.9 (0.7–1.3)
MTR
AATCTTTCCTAGAGGGCTTGG 0.373 REF
GTGGCCCTGGGAAGAAGAGAT 0.262 1.0 (0.7–1.3)
GTGGCCCTCTAGGTGACTTGG 0.190 0.9 (0.7–1.3)
GTGGCCCTGGGGAGAAGAGAT 0.045 1.4 (0.8–2.5)
GTGGCCTTCTAGATGACTTGT 0.040 0.6 (0.3–1.2)
GTGGCCCTCGAAAGGAGTTGT 0.032 0.3 (0.1–0.6)
TYMS included rs1001761, rs2847149 and, rs2853532; MTRR included rs326120, rs1532268, rs2303080, rs162036, rs2287779, rs16879334, 
rs162048, rs3776455, rs10380
rs1802059, and rs9332; MTHFR* included rs1889292, rs2274976, and rs1476413; MTHFR** included rs1801133, rs4846052, rs2066470, 
rs3737964, and rs535107; CBS included rs12613 and rs 1051319; RFC1* included rs10483080 and rs12483377; RFC1** included rs3788189 and 
rs3788190; MTHFD1* included rs2236224 and rs1256142; MTHFD1** included rs1256146 and hcv11462908; FOLR2 included rs651646 and 
rs514933; MTHFD2* included rs11126426 and rs1667599; MTHFD2** included rs828858 and rs1667627; BHMT2 included rs670220, rs592052, 
rs626105, rs682985, rs597560, and rs645112; BHMT* included rs567754, rs3733890, and rs585800; BHMT** included rs617219 and rs1915706; 
DHFR included rs2618372, rs1643638, rs1643650, rs13161245, rs836821, rs1478834, and rs380691; MTR included rs4659724, rs955516, 
rs4077829, rs12060570, rs1806505, rs6668344, rs3754255, rs10925252, rs3768139, rs3768142, rs1770449, rs7367859, rs1805087, rs2275565, 
rs1266164, rs2229276, rs10802569, rs4659743, rs3820571, rs1050993, and rs6676866.
Table 3: Haplotype associations with risks of spina bifida (Continued)
Table 4: Haplotype association with risks of conotruncal heart defects
Haplotype Frequency Odds Ratios (95% CI)
Block 19 (MTR)
AATCTTTCCTAGAGGGCTTGG 0.354 REF
GTGGCCCTGGGAAGAAGAGAT 0.272 1.1 (0.7–1.5)
GTGGCCCTCTAGGTGACTTGG 0.189 1.2 (0.8–1.8)
GTGGCCTTCTAGATGACTTGT 0.048 1.5 (0.8–3.0)
GTGGCCCTCGAAAGGAGTTGT 0.035 1.0 (0.5–2.1)
GTGGCCCTGGGGAGAAGAGAT 0.021 0.9 (0.3–2.2)
GATCTTTCCTAGAGGGCTTGG 0.013 10.7 (1.4–84.8)
Block 19 included rs4659724, rs955516, rs4077829, rs12060570, rs1806505, rs6668344, rs3754255, rs10925252, rs3768139, rs3768142, 
rs1770449, rs7367859, rs1805087, rs2275565, rs1266164, rs2229276, rs10802569, rs4659743, rs3820571, rs1050993, and
rs6676866.Page 8 of 11
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BMC Medical Genetics 2009, 10:49 http://www.biomedcentral.com/1471-2350/10/49current study. Three of the five TYMS SNPs (rs284179,
rs1001761, and rs502396) investigated here showed ele-
vated risks for spina bifida for both heterozygote or
homozygote individuals. This finding and the corre-
sponding haplotype finding (Table 3) will be important
to explore in future studies.
The strengths of this study were: 1) it investigated the
potential effects of a large number of folate pathway SNPs,
as well as investigated haplotype associations; 2) it had
population-based ascertainment of two case phenotypes
and controls; and 3) it included cases and controls born
before the US food supply was fortified with folic acid,
thus we would expect a sizable proportion of cases to have
been folate-responsive.
Conversely, our study was limited in its effect estimation
owing to small sample sizes for some comparisons. For
example, our study had 80% power to detect risks of 2.5
or more associated with genotypes that were observed in
at least 4% of controls. Another potential limitation is the
lack of information on maternal folate status. Our work-
ing hypothesis is that transient elevation in maternal
serum folate from supplementation or dietary intake
could prevent birth defects by overcoming metabolic inef-
ficiencies or transport-related issues. Absence of informa-
tion on low folate status would make it more difficult to
find putative genotypes. It is also possible that the protec-
tive effect of folic acid relates to correction of a maternal
metabolic defect, rather than the fetus. Our study was lim-
ited to infant genotype information. Thus, we were unable
to investigate the potential effects of maternal genotype.
As with any study that seeks to explore associations with a
large number of genotypes, findings are subject to chance
owing to multiple comparisons. As noted above, we con-
ducted 472 analytic comparisons and thus expected more
"statistically significant" findings to arise by chance alone.
Further, our findings may have been influenced by uncon-
trolled confounding by population stratification undetec-
table in analyses stratified or adjusted by race/ethnicity
[60,61]. Lastly, the selected SNPs represent only a fraction
of the potential variation of the studied genes. Thus, full
gene coverage was not achieved even though a large
number of SNPs was studied.
Conclusion
Despite compelling evidence that folate intake by women
in early pregnancy substantially reduces risks of selected
birth defects, the underlying mechanisms have not been
elucidated. Our study attempted to determine genetic
mechanisms responsible for folic acid's preventive effects.
Our observations do not implicate a particular folate
transport or metabolism gene to be strongly associated
with risks for spina bifida or conotruncal defects.
Although we explored a sizable number of polymorphic
areas in these genes, we clearly did not capture all the
genetic variation. Thus, these genes may continue to be
candidates for further inquiry. Alternatively, the preven-
tive role of folate may be via other biological mechanisms
such as methylation of nonfolate-related genes that partic-
ipate in the closure of the neural tube or the development
of the heart.
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